Login Register Cart 0
Generic placeholder image

Current Drug Research Reviews

Editor-in-Chief

ISSN (Print): 2589-9775
ISSN (Online): 2589-9783

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Effects of Cannabis Exposure on Adolescent Health and Development: A Narrative Review

Author(s): Ruixuan Li and Feng Tao*

Volume 17, Issue 2, 2025

Published on: 15 January, 2024

Page: [160 - 169] Pages: 10

DOI: 10.2174/0125899775273727231224185028

open_access

Abstract

Adolescence is an immature but adventurous time period of exploration. Due to rapid developments of the brain with unbalanced release of neurotransmitters, adolescents are prone to impulsivity that may carry out potentially dangerous behaviors. According to the Centers for Disease Control and Prevention, more than one-third of high school students have reported the use of cannabis or marijuana in 2019, and the trend has not declined since. Previous studies have shown that cannabis not only affects cognitive and social behaviors, but also produces psychological responses to stress. In this review, we have summarized recent studies on cannabis- produced effects during the unique period of adolescent development, and we have also briefly discussed the legalization of cannabis. Though there are slight differences between cannabis and marijuana, the major active component of them is tetrahydrocannabinol. We have used the term “cannabis” in this review. Cannabis use in adolescents causes structural and functional changes in the brain, increasing the probability of depression, which is also associated with other illicit substance use, and impairs education achievement. Given that cannabis use can cause detrimental harm to adolescents, it is suggested that adolescents should generally avoid using cannabis in a recreational manner. More preclinical and clinical studies are needed to provide detailed information for evidence-based decisions.

Keywords: Adolescence, brain, cannabis, cannabinoid receptor, substance use, legalization.

« Previous Next »
Graphical Abstract

[1]
Colizzi M, Bhattacharyya S. Cannabis: Neuropsychiatry and its effects on brain and behavior. Brain Sci 2020; 10(11): 834.
[http://dx.doi.org/10.3390/brainsci10110834] [PMID: 33182671]
[2]
Huestis MA. Cannabis (Marijuana) - Effects on human performance and behavior. Forensic Sci Rev 2002; 14(1-2): 15-60.
[PMID: 26256486]
[3]
Sharma P, Murthy P, Bharath MM. Chemistry, metabolism, and toxicology of cannabis: Clinical implications. Iran J Psychiatry 2012; 7(4): 149-56.
[PMID: 23408483]
[4]
Bonnie RJ, Scott ES. The teenage brain. Curr Dir Psychol Sci 2013; 22(2): 158-61.
[http://dx.doi.org/10.1177/0963721412471678]
[5]
Lazor T, Blondal E, Scheim A, et al. Measurement of public health impacts of cannabis legalization in Canada to reflect policy maker priorities: A rapid scoping review of instruments and content domains. Drug Alcohol Depend 2022; 236: 109463.
[http://dx.doi.org/10.1016/j.drugalcdep.2022.109463] [PMID: 35594643]
[6]
Galiègue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995; 232(1): 54-61.
[http://dx.doi.org/10.1111/j.1432-1033.1995.tb20780.x] [PMID: 7556170]
[7]
Nocerino E, Amato M, Izzo AA. Cannabis and cannabinoid receptors. Fitoterapia 2000; 71 (Suppl. 1): S6-S12.
[http://dx.doi.org/10.1016/S0367-326X(00)00171-4] [PMID: 10930707]
[8]
Kendall DA, Yudowski GA. Cannabinoid receptors in the central nervous system: Their signaling and roles in disease. Front Cell Neurosci 2017; 10: 294.
[http://dx.doi.org/10.3389/fncel.2016.00294] [PMID: 28101004]
[9]
Pertwee RG. The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids: Δ 9 ‐tetrahydrocannabinol, cannabidiol and Δ 9 ‐tetrahydrocannabivarin. Br J Pharmacol 2008; 153(2): 199-215.
[http://dx.doi.org/10.1038/sj.bjp.0707442] [PMID: 17828291]
[10]
Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG. Cannabidiol displays unexpectedly high potency as an antagonist of CB 1 and CB 2 receptor agonists in vitro. Br J Pharmacol 2007; 150(5): 613-23.
[http://dx.doi.org/10.1038/sj.bjp.0707133] [PMID: 17245363]
[11]
Tham M, Yilmaz O, Alaverdashvili M, Kelly MEM, Denovan-Wright EM, Laprairie RB. Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol‐dimethylheptyl at the type 1 and type 2 cannabinoid receptors. Br J Pharmacol 2019; 176(10): 1455-69.
[http://dx.doi.org/10.1111/bph.14440] [PMID: 29981240]
[12]
Martínez-Pinilla E, Varani K, Reyes-Resina I, et al. Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors. Front Pharmacol 2017; 8: 744.
[http://dx.doi.org/10.3389/fphar.2017.00744] [PMID: 29109685]
[13]
Laprairie RB, Bagher AM, Kelly MEM, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor. Br J Pharmacol 2015; 172(20): 4790-805.
[http://dx.doi.org/10.1111/bph.13250] [PMID: 26218440]
[14]
Galaj E, Xi ZX. Possible receptor mechanisms underlying cannabidiol effects on addictive-like behaviors in experimental animals. Int J Mol Sci 2020; 22(1): 134.
[http://dx.doi.org/10.3390/ijms22010134] [PMID: 33374481]
[15]
Saroz Y, Kho DT, Glass M, Graham ES, Grimsey NL. Cannabinoid receptor 2 (CB 2 ) signals via G-alpha-s and induces IL-6 and IL-10 cytokine secretion in human primary leukocytes. ACS Pharmacol Transl Sci 2019; 2(6): 414-28.
[http://dx.doi.org/10.1021/acsptsci.9b00049] [PMID: 32259074]
[16]
Glass M, Felder CC. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: Evidence for a Gs linkage to the CB1 receptor. J Neurosci 1997; 17(14): 5327-33.
[http://dx.doi.org/10.1523/JNEUROSCI.17-14-05327.1997] [PMID: 9204917]
[17]
Blázquez C, Chiarlone A, Bellocchio L, et al. The CB1 cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway. Cell Death Differ 2015; 22(10): 1618-29.
[http://dx.doi.org/10.1038/cdd.2015.11] [PMID: 25698444]
[18]
Palazuelos J, Aguado T, Egia A, et al. Non‐psychoactive CB 2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J 2006; 20(13): 2405-7.
[http://dx.doi.org/10.1096/fj.06-6164fje] [PMID: 17015409]
[19]
Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. Int J Mol Sci 2018; 19(3): 833.
[http://dx.doi.org/10.3390/ijms19030833] [PMID: 29533978]
[20]
Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58(3): 389-462.
[http://dx.doi.org/10.1124/pr.58.3.2] [PMID: 16968947]
[21]
Pacher P, Mukhopadhyay P, Mohanraj R, Godlewski G, Bátkai S, Kunos G. Modulation of the endocannabinoid system in cardiovascular disease: Therapeutic potential and limitations. Hypertension 2008; 52(4): 601-7.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.105.063651] [PMID: 18779440]
[22]
Di Marzo V, De Petrocellis L. Why do cannabinoid receptors have more than one endogenous ligand? Philos Trans R Soc Lond B Biol Sci 2012; 367(1607): 3216-28.
[http://dx.doi.org/10.1098/rstb.2011.0382] [PMID: 23108541]
[23]
Murataeva N, Straiker A, Mackie K. Parsing the players: 2‐arachidonoylglycerol synthesis and degradation in the CNS. Br J Pharmacol 2014; 171(6): 1379-91.
[http://dx.doi.org/10.1111/bph.12411] [PMID: 24102242]
[24]
Wittchen HU, Fröhlich C, Behrendt S, et al. Cannabis use and cannabis use disorders and their relationship to mental disorders: A 10-year prospective-longitudinal community study in adolescents. Drug Alcohol Depend 2007; 88 (Suppl. 1): S60-70.
[http://dx.doi.org/10.1016/j.drugalcdep.2006.12.013] [PMID: 17257779]
[25]
Blanco C, Hasin DS, Wall MM, et al. Cannabis use and risk of psychiatric disorders. JAMA Psychiatry 2016; 73(4): 388-95.
[http://dx.doi.org/10.1001/jamapsychiatry.2015.3229] [PMID: 26886046]
[26]
Radhakrishnan R, Wilkinson ST, D’Souza DC. Gone to pot - A review of the association between cannabis and psychosis. Front Psychiatry 2014; 5: 54.
[http://dx.doi.org/10.3389/fpsyt.2014.00054] [PMID: 24904437]
[27]
Becker MP, Collins PF, Lim KO, Muetzel RL, Luciana M. Longitudinal changes in white matter microstructure after heavy cannabis use. Dev Cogn Neurosci 2015; 16: 23-35.
[http://dx.doi.org/10.1016/j.dcn.2015.10.004] [PMID: 26602958]
[28]
Camchong J, Lim KO, Kumra S. Adverse effects of cannabis on adolescent brain development: A longitudinal study. Cereb Cortex 2017; 27(3): 1922-30.
[PMID: 26912785]
[29]
Albaugh MD, Ottino-Gonzalez J, Sidwell A, et al. Association of cannabis use during adolescence with neurodevelopment. JAMA Psychiatry 2021; 78(9): 1031.
[http://dx.doi.org/10.1001/jamapsychiatry.2021.1258] [PMID: 34132750]
[30]
Lorenzetti V, Alonso-Lana S, Youssef G, et al. Adolescent cannabis use: What is the evidence for functional brain alteration? Curr Pharm Des 2017; 22(42): 6353-65.
[http://dx.doi.org/10.2174/1381612822666160805155922] [PMID: 27514709]
[31]
Rais M, Cahn W, Van Haren N, et al. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. Am J Psychiatry 2008; 165(4): 490-6.
[http://dx.doi.org/10.1176/appi.ajp.2007.07071110] [PMID: 18281413]
[32]
Koenders L, Machielsen MWJ, van der Meer FJ, et al. Brain volume in male patients with recent onset schizophrenia with and without cannabis use disorders. J Psychiatry Neurosci 2015; 40(3): 197-206.
[http://dx.doi.org/10.1503/jpn.140081] [PMID: 25510948]
[33]
Yücel M, Solowij N, Respondek C, et al. Regional brain abnormalities associated with long-term heavy cannabis use. Arch Gen Psychiatry 2008; 65(6): 694-701.
[http://dx.doi.org/10.1001/archpsyc.65.6.694] [PMID: 18519827]
[34]
Scott JC, Rosen AFG, Moore TM, et al. Cannabis use in youth is associated with limited alterations in brain structure. Neuropsychopharmacology 2019; 44(8): 1362-9.
[http://dx.doi.org/10.1038/s41386-019-0347-2] [PMID: 30780151]
[35]
Dragt S, Nieman DH, Becker HE, et al. Age of onset of cannabis use is associated with age of onset of high-risk symptoms for psychosis. Can J Psychiatry 2010; 55(3): 165-71.
[http://dx.doi.org/10.1177/070674371005500308] [PMID: 20370967]
[36]
Beggiato S, Borelli AC, Tomasini MC, et al. Long-lasting alterations of hippocampal GABAergic neurotransmission in adult rats following perinatal Δ9-THC exposure. Neurobiol Learn Mem 2017; 139: 135-43.
[http://dx.doi.org/10.1016/j.nlm.2016.12.023] [PMID: 28104530]
[37]
Stiglick A, Llewellyn ME, Kalant H. Residual effects of prolonged cannabis treatment on shuttle-box avoidance in the rat. Psychopharmacology 1984; 84(4): 476-9.
[http://dx.doi.org/10.1007/BF00431452] [PMID: 6441947]
[38]
Scott JC, Wolf DH, Calkins ME, et al. Cognitive functioning of adolescent and young adult cannabis users in the Philadelphia neurodevelopmental cohort. Psychol Addict Behav 2017; 31(4): 423-34.
[http://dx.doi.org/10.1037/adb0000268] [PMID: 28414475]
[39]
Yücel M, Lorenzetti V, Suo C, et al. Hippocampal harms, protection and recovery following regular cannabis use. Transl Psychiatry 2016; 6(1): e710.
[http://dx.doi.org/10.1038/tp.2015.201] [PMID: 26756903]
[40]
Wolf SA, Bick-Sander A, Fabel K, et al. Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis. Cell Commun Signal 2010; 8(1): 12.
[http://dx.doi.org/10.1186/1478-811X-8-12] [PMID: 20565726]
[41]
Esposito G, Scuderi C, Valenza M, et al. Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement. PLoS One 2011; 6(12): e28668.
[http://dx.doi.org/10.1371/journal.pone.0028668] [PMID: 22163051]
[42]
Milich R, Lynam D, Zimmerman R, et al. Differences in young adult psychopathology among drug abstainers, experimenters, and frequent users. J Subst Abuse 2000; 11(1): 69-88.
[http://dx.doi.org/10.1016/S0899-3289(99)00021-8] [PMID: 10756515]
[43]
Bolanis D, Orri M, Castellanos-Ryan N, et al. Cannabis use, depression and suicidal ideation in adolescence: Direction of associations in a population based cohort. J Affect Disord 2020; 274: 1076-83.
[http://dx.doi.org/10.1016/j.jad.2020.05.136] [PMID: 32663935]
[44]
Bovasso GB. Cannabis abuse as a risk factor for depressive symptoms. Am J Psychiatry 2001; 158(12): 2033-7.
[http://dx.doi.org/10.1176/appi.ajp.158.12.2033] [PMID: 11729021]
[45]
Hayatbakhsh MR, Najman JM, Jamrozik K, Mamun AA, Alati R, Bor W. Cannabis and anxiety and depression in young adults: A large prospective study. J Am Acad Child Adolesc Psychiatry 2007; 46(3): 408-17.
[http://dx.doi.org/10.1097/chi.0b013e31802dc54d] [PMID: 17314727]
[46]
Degenhardt L, Hall W, Lynskey M. Exploring the association between cannabis use and depression. Addiction 2003; 98(11): 1493-504.
[http://dx.doi.org/10.1046/j.1360-0443.2003.00437.x] [PMID: 14616175]
[47]
Harder VS, Stuart EA, Anthony JC. Adolescent cannabis problems and young adult depression: Male-female stratified propensity score analyses. Am J Epidemiol 2008; 168(6): 592-601.
[http://dx.doi.org/10.1093/aje/kwn184] [PMID: 18687663]
[48]
Connor JP, Stjepanović D, Le Foll B, Hoch E, Budney AJ, Hall WD. Cannabis use and cannabis use disorder. Nat Rev Dis Primers 2021; 7(1): 16.
[http://dx.doi.org/10.1038/s41572-021-00247-4] [PMID: 33627670]
[49]
Delling FN, Vittinghoff E, Dewland TA, et al. Does cannabis legalisation change healthcare utilisation? A population-based study using the healthcare cost and utilisation project in Colorado, USA. BMJ Open 2019; 9(5): e027432.
[http://dx.doi.org/10.1136/bmjopen-2018-027432] [PMID: 31092662]
[50]
Karila L, Roux P, Rolland B, et al. Acute and long-term effects of cannabis use: A review. Curr Pharm Des 2014; 20(25): 4112-8.
[http://dx.doi.org/10.2174/13816128113199990620] [PMID: 24001294]
[51]
Fergusson DM, Horwood LJ. Does cannabis use encourage other forms of illicit drug use? Addiction 2000; 95(4): 505-20.
[http://dx.doi.org/10.1046/j.1360-0443.2000.9545053.x] [PMID: 10829327]
[52]
Morral AR, McCaffrey DF, Paddock SM. Reassessing the marijuana gateway effect. Addiction 2002; 97(12): 1493-504.
[http://dx.doi.org/10.1046/j.1360-0443.2002.00280.x] [PMID: 12472629]
[53]
Hall WD, Lynskey M. Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs. Drug Alcohol Rev 2005; 24(1): 39-48.
[http://dx.doi.org/10.1080/09595230500126698] [PMID: 16191720]
[54]
Yamaguchi K, Kandel DB. Patterns of drug use from adolescence to young adulthood: III. Predictors of progression. Am J Public Health 1984; 74(7): 673-81.
[http://dx.doi.org/10.2105/AJPH.74.7.673] [PMID: 6742253]
[55]
Wagner FA, Anthony JC. Into the world of illegal drug use: Exposure opportunity and other mechanisms linking the use of alcohol, tobacco, marijuana, and cocaine. Am J Epidemiol 2002; 155(10): 918-25.
[http://dx.doi.org/10.1093/aje/155.10.918] [PMID: 11994231]
[56]
Secades-Villa R, Garcia-Rodríguez O, Jin CJ, Wang S, Blanco C. Probability and predictors of the cannabis gateway effect: A national study. Int J Drug Policy 2015; 26(2): 135-42.
[http://dx.doi.org/10.1016/j.drugpo.2014.07.011] [PMID: 25168081]
[57]
Fergusson DM, Boden JM, Horwood LJ. Cannabis use and other illicit drug use: Testing the cannabis gateway hypothesis. Addiction 2006; 101(4): 556-69.
[http://dx.doi.org/10.1111/j.1360-0443.2005.01322.x] [PMID: 16548935]
[58]
Friedman AL, Meurice C, Jutkiewicz EM. Effects of adolescent Δ9-tetrahydrocannabinol exposure on the behavioral effects of cocaine in adult Sprague–Dawley rats. Exp Clin Psychopharmacol 2019; 27(4): 326-37.
[http://dx.doi.org/10.1037/pha0000276] [PMID: 30932503]
[59]
Lecca D, Scifo A, Pisanu A, et al. Adolescent cannabis exposure increases heroin reinforcement in rats genetically vulnerable to addiction. Neuropharmacology 2020; 166: 107974.
[http://dx.doi.org/10.1016/j.neuropharm.2020.107974] [PMID: 32007624]
[60]
van Leeuwen AP, Verhulst FC, Reijneveld SA, Vollebergh WAM, Ormel J, Huizink AC. Can the gateway hypothesis, the common liability model and/or, the route of administration model predict initiation of cannabis use during adolescence? A survival analysis--the TRAILS study. J Adolesc Health 2011; 48(1): 73-8.
[http://dx.doi.org/10.1016/j.jadohealth.2010.05.008] [PMID: 21185527]
[61]
Agrawal A, Lynskey MT. Tobacco and cannabis co-occurrence: Does route of administration matter? Drug Alcohol Depend 2009; 99(1-3): 240-7.
[http://dx.doi.org/10.1016/j.drugalcdep.2008.08.007] [PMID: 18926646]
[62]
Huizink AC, Levälahti E, Korhonen T, et al. Tobacco, cannabis, and other illicit drug use among Finnish adolescent twins: causal relationship or correlated liabilities? J Stud Alcohol Drugs 2010; 71(1): 5-14.
[http://dx.doi.org/10.15288/jsad.2010.71.5] [PMID: 20105408]
[63]
Fergusson DM, Boden JM. Cannabis use and later life outcomes. Addiction 2008; 103(6): 969-76.
[http://dx.doi.org/10.1111/j.1360-0443.2008.02221.x] [PMID: 18482420]
[64]
Lorenzetti V, Hoch E, Hall W. Adolescent cannabis use, cognition, brain health and educational outcomes: A review of the evidence. Eur Neuropsychopharmacol 2020; 36: 169-80.
[http://dx.doi.org/10.1016/j.euroneuro.2020.03.012] [PMID: 32268974]
[65]
Lynskey M, Hall W. The effects of adolescent cannabis use on educational attainment: A review. Addiction 2000; 95(11): 1621-30.
[http://dx.doi.org/10.1046/j.1360-0443.2000.951116213.x] [PMID: 11219366]
[66]
Pacula RL, Chriqui JF, Reichmann DA, Terry-McElrath YM. State medical marijuana laws: Understanding the laws and their limitations. J Public Health Policy 2002; 23(4): 413-39.
[http://dx.doi.org/10.2307/3343240] [PMID: 12532682]
[67]
Fried P, Watkinson B, Gray R. Neurocognitive consequences of marihuana—a comparison with pre-drug performance. Neurotoxicol Teratol 2005; 27(2): 231-9.
[http://dx.doi.org/10.1016/j.ntt.2004.11.003] [PMID: 15734274]
[68]
Mokrysz C, Landy R, Gage SH, Munafò MR, Roiser JP, Curran HV. Are IQ and educational outcomes in teenagers related to their cannabis use? A prospective cohort study. J Psychopharmacol 2016; 30(2): 159-68.
[http://dx.doi.org/10.1177/0269881115622241] [PMID: 26739345]
[69]
Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA 2012; 109(40): E2657-64.
[http://dx.doi.org/10.1073/pnas.1206820109] [PMID: 22927402]
[70]
Horwood LJ, Fergusson DM, Hayatbakhsh MR, et al. Cannabis use and educational achievement: Findings from three Australasian cohort studies. Drug Alcohol Depend 2010; 110(3): 247-53.
[http://dx.doi.org/10.1016/j.drugalcdep.2010.03.008] [PMID: 20456872]
[71]
Degenhardt L, Coffey C, Carlin JB, Swift W, Moore E, Patton GC. Outcomes of occasional cannabis use in adolescence: 10-year follow-up study in Victoria, Australia. Br J Psychiatry 2010; 196(4): 290-5.
[http://dx.doi.org/10.1192/bjp.bp.108.056952] [PMID: 20357305]
[72]
Swaim RC, Beauvais F, Chavez EL, Oetting ER. The effect of school dropout rates on estimates of adolescent substance use among three racial/ethnic groups. Am J Public Health 1997; 87(1): 51-5.
[http://dx.doi.org/10.2105/AJPH.87.1.51] [PMID: 9065226]
[73]
Fergusson DM, Horwood LJ, Beautrais AL. Cannabis and educational achievement. Addiction 2003; 98(12): 1681-92.
[http://dx.doi.org/10.1111/j.1360-0443.2003.00573.x] [PMID: 14651500]
[74]
Verweij KJH, Huizink AC, Agrawal A, Martin NG, Lynskey MT. Is the relationship between early-onset cannabis use and educational attainment causal or due to common liability? Drug Alcohol Depend 2013; 133(2): 580-6.
[http://dx.doi.org/10.1016/j.drugalcdep.2013.07.034] [PMID: 23972999]
[75]
Lynne-Landsman SD, Livingston MD, Wagenaar AC. Effects of state medical marijuana laws on adolescent marijuana use. Am J Public Health 2013; 103(8): 1500-6.
[http://dx.doi.org/10.2105/AJPH.2012.301117] [PMID: 23763418]
[76]
McKenna GJ. The current status of medical marijuana in the United States. Hawaii J Med Public Health 2014; 73(4): 105-8.
[PMID: 24765557]
[77]
Hoffmann DE, Weber E. Medical marijuana and the law. N Engl J Med 2010; 362(16): 1453-7.
[http://dx.doi.org/10.1056/NEJMp1000695] [PMID: 20410512]
[78]
Mead A. Legal and regulatory issues governing cannabis and cannabis-derived products in the United States. Front Plant Sci 2019; 10: 697.
[http://dx.doi.org/10.3389/fpls.2019.00697] [PMID: 31263468]
[79]
Ghosh TS, Vigil DI, Maffey A, et al. Lessons learned after three years of legalized, recreational marijuana: The Colorado experience. Prev Med 2017; 104: 4-6.
[http://dx.doi.org/10.1016/j.ypmed.2017.02.021] [PMID: 28232101]
[80]
Ryan JE, McCabe SE, Boyd CJ. Medicinal cannabis: Policy, patients, and providers. Policy Polit Nurs Pract 2021; 22(2): 126-33.
[http://dx.doi.org/10.1177/1527154421989609] [PMID: 33567970]
[81]
State Medical Cannabis Laws. National Conference of State Legislatures 2022.
[82]
Yashar Eshraghi DD. Cannabis Regulations. In: Cannabinoids and Pain. 2021; pp. 9-14.
[http://dx.doi.org/10.1007/978-3-030-69186-8_2]
[83]
McMichael BJ, Van Horn RL, Viscusi WK. The impact of cannabis access laws on opioid prescribing. J Health Econ 2020; 69: 102273.
[http://dx.doi.org/10.1016/j.jhealeco.2019.102273] [PMID: 31865260]
[84]
Vyas MB, LeBaron VT, Gilson AM. The use of cannabis in response to the opioid crisis: A review of the literature. Nurs Outlook 2018; 66(1): 56-65.
[http://dx.doi.org/10.1016/j.outlook.2017.08.012] [PMID: 28993073]
[85]
Bradford AC, Bradford WD, Abraham A, Bagwell Adams G. Association between us state medical cannabis laws and opioid prescribing in the medicare part d population. JAMA Intern Med 2018; 178(5): 667-72.
[http://dx.doi.org/10.1001/jamainternmed.2018.0266] [PMID: 29610897]
[86]
Knishkowy B. Medical cannabis for pain in adolescence. J Pain Manag 2016; 9(4): 415-21.
[87]
Hopfer C. Implications of marijuana legalization for adolescent substance use. Subst Abus 2014; 35(4): 331-5.
[http://dx.doi.org/10.1080/08897077.2014.943386] [PMID: 25127003]
[88]
Cil G, Winters KC, Austin SC, et al. Legalization and retail availability of recreational marijuana and adolescent use in schools. Health Econ 2023; hec.4763.
[http://dx.doi.org/10.1002/hec.4763] [PMID: 37801408]
[89]
Mennis J, Stahler GJ, McKeon TP. Criminal justice referrals to cannabis use disorder treatment among adolescents and young adults following recreational cannabis legalization in the United States. J Addict Med 2023; 17(6): 725-8.
[http://dx.doi.org/10.1097/ADM.0000000000001219] [PMID: 37934545]

Rights & Permissions Print Cite
Article Metrics
37
1
Wayfinder Image
© 2026 Bentham Science Publishers | Privacy Policy